Home › Melanoma › Arizona › Tucson
Melanoma clinical trials in Tucson, AZ
5 studies for Melanoma are looking for participants at sites in and around Tucson (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
RecruitingPhase 1/2
- Banner Health, Tucson
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
RecruitingPhase 1/2
- University of Arizona, Tucson
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
RecruitingPhase 1/2
- Research Site 111, Tucson
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
RecruitingPhase 1/2
- Arizona Cancer Center at UMC North/University Medical Center, Tucson
Project: Every Child for Younger Patients With Cancer
RecruitingObservational study
- Banner University Medical Center - Tucson, Tucson
About Melanoma
Melanoma is the most serious type of skin cancer. Most have a black or black-blue area. Learn the 'ABCDE' of what to watch for and treatment options.
More about Melanoma on MedlinePlus
Melanoma trials in other cities
- Houston, TX61 studies
- New York City, NY41 studies
- Nashville, TN34 studies
- Los Angeles, CA34 studies
- Pittsburgh, PA31 studies
- Boston, MA25 studies
- St. Louis, MO23 studies
- Durham, NC22 studies
- Philadelphia, PA22 studies
- Tampa, FL21 studies
- Columbus, OH21 studies
- Dallas, TX21 studies
Other studies in Tucson
- Obesity20 studies
- Breast Cancer18 studies
- Non-Small Cell Lung Cancer18 studies
- Overweight17 studies
- Metastatic Cancer14 studies
- Type 2 Diabetes13 studies
- Cancer (all types)12 studies
- Prostate Cancer12 studies
- Colorectal Cancer11 studies
- Cardiovascular Disease11 studies
- Steatotic Liver Disease10 studies
- Acute Myeloid Leukemia10 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.